Developing sciencedelivering therapies
We are pioneers in harnessing bacteria as a revolutionary new class of medicines – called live biotherapeutics.
From asthma to cancer, we conduct world-leading research to identify live biotherapeutics with drug-like functionality to treat a range of diseases.
We are uniquely positioned to rapidly translate our research into regulated, safe and efficacious therapies for patients.
Update on phase 1 clinical trial in respect of Blautix
For the period ended 30 June 2016
Commenced dosing in a phase 1 clinical trial